Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke
RATIONALE: Contingency management is a behavioral treatment approach that provides immediate rewards for positive change in behavior such as quitting smoking. In this protocol, contingency management will be in the form of a cash reward. A smoking cessation (stop-smoking) program that combines contingency management with bupropion and counseling may be effective in helping cancer survivors stop smoking.
PURPOSE: Randomized clinical trial to compare the effectiveness of bupropion and counseling with or without contingency management in helping cancer survivors stop smoking.
|Cancer Survivor Unspecified Adult Solid Tumor, Protocol Specific||Behavioral: smoking cessation intervention Drug: bupropion hydrochloride|
|Study Design:||Allocation: Randomized
Primary Purpose: Prevention
|Official Title:||Contingency Management to Enhance Smoking Cessation for Cancer Survivors: A Proof of Concept Trial|
|Study Start Date:||February 2004|
|Study Completion Date:||August 2004|
- Compare the feasibility of a multi-component smoking cessation intervention comprising bupropion and counseling with or without contingency management (cash reward) for cancer survivors who continue to smoke.
- Compare 7-day point-prevalence abstinence rates in patients treated with these smoking cessation interventions.
- Determine the characteristics of these patients that predict success at quitting smoking.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 smoking cessation intervention arms.
- Arm I: Patients receive oral bupropion twice daily on weeks 1-12 and brief practical counseling (i.e., problem-solving strategies, stimulus control, stress management, and social support) on weeks 1-6.
- Arm II: Patients receive treatment as in arm I and contingency management (i.e., monetary reinforcement for not smoking) on weeks 1-6.
In both arms, treatment continues in the absence of unacceptable toxicity.
Patients are followed at 12 and 24 weeks after the completion of the smoking cessation interventions.
PROJECTED ACCRUAL: A total of 100 patients (50 per intervention arm) will be accrued for this study within 8 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00079469
|United States, Maryland|
|Tobacco Control Research Branch|
|Rockville, Maryland, United States, 20852|
|Principal Investigator:||Glen D. Morgan, PhD||NCI - Division of Cancer Control and Population Science|
|OverallOfficial:||Sandra J. Schaefer, RN, BSN, OCN||National Cancer Institute (NCI)|